Skip to content
10-Q

Quarterly Report

Seres Therapeutics, Inc. MCRB

0001193125-26-205434

← back to feed
Filed
May 5, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted Q1 2026 · Mar 31, 2026 9.58M sh
Shares Diluted Q1 2026 · Mar 31, 2025 8.71M sh
Capex Q1 2026 · Mar 31, 2026 $0
Capex Q1 2026 · Mar 31, 2025 $34K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$16.36M
Operating Cash Flow Q1 2026 · Mar 31, 2025 $26.91M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $29.83M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $45.77M
Stockholders Equity Q1 2026 · Mar 31, 2026 $26.5M
Stockholders Equity Q1 2026 · Dec 31, 2025 $44.22M
Stockholders Equity Q1 2026 · Mar 31, 2025 $50.47M
Stockholders Equity Q1 2026 · Dec 31, 2024 $13.78M
Current Liabilities Q1 2026 · Mar 31, 2026 $19.34M
Current Liabilities Q1 2026 · Dec 31, 2025 $19.32M
Total Liabilities Q1 2026 · Mar 31, 2026 $91.12M
Total Liabilities Q1 2026 · Dec 31, 2025 $93.98M
Current Assets Q1 2026 · Mar 31, 2026 $31.84M
Current Assets Q1 2026 · Dec 31, 2025 $49.38M
Total Assets Q1 2026 · Mar 31, 2026 $117.62M
Total Assets Q1 2026 · Dec 31, 2025 $138.19M
Eps Diluted Q1 2026 · Mar 31, 2026 −$2.08
Eps Diluted Q1 2026 · Mar 31, 2025 $3.75
Eps Basic Q1 2026 · Mar 31, 2026 −$2.08
Eps Basic Q1 2026 · Mar 31, 2025 $3.76
Sga Expense Q1 2026 · Mar 31, 2026 $8.07M
Sga Expense Q1 2026 · Mar 31, 2025 $11.89M
Rd Expense Q1 2026 · Mar 31, 2026 $13.2M
Rd Expense Q1 2026 · Mar 31, 2025 $11.82M
Net Income Q1 2026 · Mar 31, 2026 −$19.91M
Net Income Q1 2026 · Mar 31, 2025 $32.68M
Operating Income Q1 2026 · Mar 31, 2026 −$20.91M
Operating Income Q1 2026 · Mar 31, 2025 −$27.24M